<DOC>
	<DOCNO>NCT00967330</DOCNO>
	<brief_summary>This 2 arm study compare effect Avastin + irinotecan versus temozolomide , combination conventional involved field radiotherapy , patient newly diagnose glioblastoma non-methylated MGMT promoter . Patients randomize 3:1 receive Avastin 10mg/kg iv every 2 week + irinotecan 125mg/m2 iv every 2 week , temozolomide 75mg/m2 po daily radiotherapy follow 6 cycle temozolomide 150-200mg/m2 po daily day 1-5 4 week cycle . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Irinotecan Versus Temozolomide Radiochemistry Patients With Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>adult patient , 1870 year age ; glioblastoma , confirm histologically ; previous chemotherapy radiotherapy glioblastoma ; nonmethylated MGMT promoter tumor . prior systemic treatment glioblastoma multiforme ; prior treatment Avastin ; significant cardiovascular disease ; active malignant disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>